STOCK TITAN

Innoviva (INVA) director receives RSU and stock option grants as board compensation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Innoviva, Inc. director Linden Josephine reported equity compensation awards tied to their appointment to the Board on May 18, 2026. They received 9,461 shares of common stock and a separate 5,733-share restricted stock unit grant, all at no cash cost. In addition, they were granted non-statutory stock options for 9,166 shares of common stock at an exercise price of $21.80 per share, expiring in 2036. The RSUs vest over two years, while the options and additional RSUs vest at the earlier of the next annual stockholder meeting or one year after the grant date, subject to continued service and certain acceleration events.

Positive

  • None.

Negative

  • None.
Insider Linden Josephine
Role null
Type Security Shares Price Value
Grant/Award Non-statutory Stock Option 9,166 $0.00 --
Grant/Award Common Stock 5,733 $0.00 --
Grant/Award Common Stock 9,461 $0.00 --
Holdings After Transaction: Non-statutory Stock Option — 9,166 shares (Direct, null); Common Stock — 5,733 shares (Direct, null)
Footnotes (1)
  1. The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon their appointment to the Issuer's Board of Directors ("Board") on May 18, 2026 (the "Effective Date"). The RSUs vest in equal installments on each of the first two anniversaries of the Effective Date. Options and additional RSUs were granted and will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of the Effective Date, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability.
Common stock grant 9,461 shares Common stock awarded at $0.00 per share on May 18, 2026
Additional RSU grant 5,733 shares Restricted stock units awarded on May 18, 2026
Stock options granted 9,166 options Non-statutory stock options granted on May 18, 2026
Option exercise price $21.80 per share Exercise price for non-statutory stock options
Options expiration May 17, 2036 Expiration date of non-statutory stock options
Shares held after grant 15,194 shares Total common shares following the 9,461-share award
RSU holding after grant 5,733 units Total RSUs following the 5,733-unit award entry
Options held after grant 9,166 options Total non-statutory options following the grant
restricted stock units ("RSUs") financial
"The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
non-statutory stock options financial
"granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon their appointment"
Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.
Outside Director financial
"subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date"
change in control financial
"in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan)"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2026 Equity Incentive Plan financial
"as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Linden Josephine

(Last)(First)(Middle)
C/O INNOVIVA, INC.
1350 OLD BAYSHORE HIGHWAY, SUITE 400

(Street)
BURLINGAME CALIFORNIA 94010

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Innoviva, Inc. [ INVA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026A5,733(1)(2)A$05,733D
Common Stock05/18/2026A9,461(1)(3)A$015,194D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-statutory Stock Option$21.805/18/2026A9,16605/18/2027(1)(3)05/17/2036Common Stock9,166$09,166D
Explanation of Responses:
1. The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon their appointment to the Issuer's Board of Directors ("Board") on May 18, 2026 (the "Effective Date").
2. The RSUs vest in equal installments on each of the first two anniversaries of the Effective Date.
3. Options and additional RSUs were granted and will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of the Effective Date, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability.
/s/ Josephine Linden05/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Linden Josephine receive from Innoviva (INVA)?

Linden Josephine received equity compensation as a director, including 9,461 shares of common stock, 5,733 additional restricted stock units, and non-statutory stock options for 9,166 shares at a $21.80 exercise price. These awards reflect standard Board-related compensation, not open-market purchases.

When do Linden Josephine’s Innoviva (INVA) RSUs vest?

One Innoviva RSU grant vests in equal installments on each of the first two anniversaries of May 18, 2026. Additional RSUs vest at the earlier of the next annual stockholder meeting or one year after that date, assuming continued service as an Outside Director.

What are the terms of Linden Josephine’s Innoviva (INVA) stock options?

Linden Josephine was granted non-statutory stock options for 9,166 Innoviva shares at a $21.80 exercise price. These options are scheduled to vest at the earlier of the next annual stockholder meeting or one year after May 18, 2026, and expire on May 17, 2036.

Did Linden Josephine buy or sell Innoviva (INVA) shares in this Form 4?

This Form 4 does not show open-market buying or selling. It reports equity grants: common stock, restricted stock units, and stock options awarded as director compensation, all at a reported transaction price of $0.00 per share rather than market purchases or sales.

What triggers accelerated vesting of Innoviva (INVA) awards for Linden Josephine?

The awards provide for accelerated vesting upon Linden Josephine’s death, disability, or certain change in control events defined in Innoviva’s 2026 Equity Incentive Plan, so long as they have not experienced a termination before the applicable change in control, death, or disability event.